Clinical Trial Update: Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial [Phase 1]

View source ↗

Summary

Phase 1 GD2-targeted CAR-T cell therapy (GD2CART) for recurrent/refractory neuroblastoma and osteosarcoma has a suspended status as of the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Osteosarcoma

Drugs mentioned

• GD2CART (GD2-targeted CAR-T cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma | Phase 1 | Status: SUSPENDED